<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Stavudine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00649</strong>&#160; (APRD00440)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against <span class="caps">HIV</span>. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00649/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00649/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00649.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00649.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00649.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00649.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00649.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00649">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Estavudina</td><td>Spanish</td><td>INN</td></tr><tr><td>Sanilvudine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>JAN</td></tr><tr><td>Stavudin</td><td>German</td><td>INN</td></tr><tr><td>Stavudine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, BAN, USAN</td></tr><tr><td>Stavudinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Actastav</td><td>Actavis</td></tr><tr><td>Ai Fu Ding</td><td>Wujing Medicine</td></tr><tr><td>Avostav</td><td>Ranbaxy Laboratories</td></tr><tr><td>Estavudox</td><td>Biotoscana</td></tr><tr><td>Exvihr</td><td>Biogen</td></tr><tr><td>Flamistav</td><td>Flamingo Pharmacueticals</td></tr><tr><td>Landstav</td><td>Landsteiner</td></tr><tr><td>Lion</td><td>Filaxis</td></tr><tr><td>Mai Si Ting</td><td>Meijisi Pharmaceutical</td></tr><tr><td>S.T.V.</td><td>Ivax</td></tr><tr><td>Sazi</td><td>NEGPF</td></tr><tr><td>Stadine</td><td>Stadine</td></tr><tr><td>Stag</td><td>Hetero</td></tr><tr><td>Stamar</td><td>LKM</td></tr><tr><td>Stavex</td><td>Aurobindo</td></tr><tr><td>Stavir</td><td>Cipla</td></tr><tr><td>Stavubergen</td><td>Paylos</td></tr><tr><td>Zerit</td><td>Bristol-Myers Squibb</td></tr><tr><td>Zerit XR</td><td>Bristol-Myers Squibb</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Coviro</td><td>Stavudine and Lamivudine</td></tr><tr><td>Emduo</td><td>Stavudine and Lamivudine</td></tr><tr><td>Emduo-JR</td><td>Stavudine and Lamivudine</td></tr><tr><td>Emduo-N</td><td>Stavudine, Lamivudine, Nevirapine</td></tr><tr><td>Emtri</td><td>Stavudine, Lamivudine, Nevirapine</td></tr><tr><td>Emtri JR</td><td>Stavudine, Lamivudine, Nevirapine</td></tr><tr><td>Lamitec-S </td><td>Stavudine and Lamivudine</td></tr><tr><td>Lamivir-S </td><td>Stavudine and Lamivudine</td></tr><tr><td>Lamostad</td><td>Stavudine and Lamivudine</td></tr><tr><td>Lamostad-N</td><td>Stavudine, Lamivudine, Nevirapine</td></tr><tr><td>Lazid</td><td>Stavudine and Lamivudine</td></tr><tr><td>Maxivir</td><td>Stavudine, Lamivudine, Nevirapine</td></tr><tr><td>Medilam</td><td>Stavudine and Lamivudine</td></tr><tr><td>Nevitrio</td><td>Stavudine, Lamivudine, Nevirapine</td></tr><tr><td>Sonke-LamiNevStav </td><td>Stavudine, Lamivudine, Nevirapine</td></tr><tr><td>Sonke-Lastad</td><td>Stavudine and Lamivudine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-hiv-agents">Anti-HIV Agents</a></li>
<li><a href="/mesh/antimetabolites">Antimetabolites</a></li>
<li><a href="/mesh/reverse-transcriptase-inhibitors">Reverse Transcriptase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>3056-17-5</td></tr><tr><th>Weight</th><td>Average: 224.2133<br>Monoisotopic: 224.079706882</td></tr><tr><th>Chemical Formula</th><td>C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>XNKLLVCARDGLGL-JGVFFNPUSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organooxygen Compounds</td></tr><tr><th>Class</th><td>Carbohydrates and Carbohydrate Conjugates</td></tr><tr><th>Subclass</th><td>Glycosyl Compounds</td></tr><tr><th>Direct parent</th><td>Pyrimidine Nucleosides and Analogues</td></tr><tr><th>Alternative parents</th><td>Pyrimidones; Hydropyrimidines; Dihydrofurans; Primary Alcohols; Ethers; Polyamines</td></tr><tr><th>Substituents</th><td>pyrimidone; pyrimidine; hydropyrimidine; dihydrofuran; primary alcohol; ether; polyamine; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyrimidine nucleosides and analogues. These are compounds comprising a pyrimidine base attached to a sugar.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of human immunovirus (HIV) infections.</td></tr><tr><th>Pharmacodynamics</th><td>Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.</td></tr><tr><th>Mechanism of action</th><td>Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.</td></tr><tr><th>Absorption</th><td>Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%).</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>46 &#177; 21 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>Negligible</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Phosphorylated intracellularly to stavudine triphosphate, the active substrate for HIV-reverse transcriptase.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>0.8-1.5 hours (in adults)</td></tr><tr><th>Clearance</th><td><ul>
	<li>Renal cl=272 mL/min [Healthy subjects receiving 80 mg PO]</li>
	<li>594 +/- 164 mL/min [<span class="caps">HIV</span>-infected adult and pediatric patients following 1-hour IV infusion]</li>
	<li>9.75 +/- 3.76 mL/min/kg [<span class="caps">HIV</span>- Exposed or -Infected Pediatric Patients(Age 5 weeks &#8211; 15 years) following 1-hour IV infusion]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Side effects include peripheral neuropathy tingling, burning, numbness, or pain in the hands or feet), fatal lactic acidosis has been reported in patients treated with stavudine (ZERIT) in combination with other antiretroviral agents, severe liver enlargement, inflammation (pain and swelling) of the liver, and liver failure.</td></tr><tr><th>Affected organisms</th><td><ul><li>Human Immunodeficiency Virus</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9889</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9381</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8958</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7949</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9073</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7979</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9226</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6707</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8872</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6011</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9336</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9269</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9445</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7275
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8131
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.6132
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.7802 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9413
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9375
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bristol myers squibb co</li>
<li>Aurobindo pharma ltd</li>
<li>Hetero drugs ltd</li>
<li>Matrix laboratories ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Bristol myers squibb co pharmaceutical research institute</li>
<li>Cipla ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://www.bms.com">Bristol-Myers Squibb Co.</a></li>
<li><a href="http://www.camberpharma.com">Camber Pharmaceuticals Inc.</a></li>
<li><a href="http://www.cipla.com">Cipla Ltd.</a></li>
<li><a href="http://www.davapharma.com">DAVA Pharmaceuticals</a></li>
<li>Dept Health Central Pharmacy</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li>E.R. Squibb and Sons LLC</li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li><a href="http://www.heterodrugs.com">Hetero Drugs Ltd.</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.matrixlabsindia.com">Matrix Laboratories Ltd.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Tya Pharmaceuticals</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00495">Zidovudine</a></td><td>Zidovudine may decrease the efficacy of stavudine. Concomitant therapy should be avoided. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>